Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Altasciences to guide development of RAP-103 peptide as chemical nerve agent therapeutic

May 23, 2019

Encouraging phase I data reported for dAd5GNE anti-cocaine vaccine

May 15, 2019

Opioids impervious to GLP-1 agonists

April 26, 2019

Phase II study of AXS-05 for smoking cessation meets prespecified primary endpoint

April 16, 2019

Chronos Therapeutics presents orexin receptor antagonists

March 22, 2019

RGFP-966, an HDAC3 inhibitor, suppresses drug-seeking behavior in rats

Feb. 21, 2019

GPR39 agonist reduces alcohol intake in mouse model of alcohol use disorder

Feb. 19, 2019

Addex and Indivior intend to accelerate additional GABA-B PAM compounds for addiction

Feb. 14, 2019

Antidote Therapeutics to collaborate with NCI on development of ATI-1013

Feb. 8, 2019

Phase Ib data support expansion of indication for BioXcel's BXCL-501

Feb. 5, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...